ClinicalTrials.gg
CompletedNCT02713230Updated Dec 3, 2020Results posted

Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery

A Phase 3 interventional study of bupivacaine liposome injectable suspension and bupivacaine liposome injectable suspension in Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-03.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.

Enrollment
3rd of 36
156 · median 60
Started
2016
with 2 others
Phase 3
6 of 36
1 open now
Registered
20th of 36
by date
Lead sponsor
7 of 36
Pacira Pharmaceuticals, Inc

Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 3rd largest by enrollment, is one of 3 that started in 2016, is one of 6 in phase 3, and was the 20th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Liposomal Bupivacaine in Pain, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 155 adult subjects undergoing primary unilateral total shoulder arthroplasty or rotator cuff repair with general anesthesia

Read the detailed description

On Day 0, eligible subjects will be randomized in a 1:1 ratio to receive a single dose of EXPAREL 133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total volume of 20 mL or placebo 20 mL. Study drug (EXPAREL or placebo) will be administered in a blinded manner via an ultrasound guided single-dose brachial plexus block at least 1 hour prior to surgery.

Postsurgical assessments will include pain intensity scores using a 10-cm visual analog scale (VAS); total postsurgical opioid consumption; overall benefit of analgesia score (OBAS) questionnaire; subject satisfaction with overall analgesia using a 5 point Likert scale; neurological assessment; sensory function assessment; motor function assessment; discharge readiness; unscheduled phone calls or office visits related to pain; 12-lead ECGs; vital sign measurements; and clinical laboratory tests. Adverse events will be recorded from the time the informed consent form is signed through postsurgical Day 29.

Follow-up visits will be scheduled for all subjects on postsurgical Days 5 and 10. A follow-up phone call will be made on postsurgical Day 29.

A population Pharmacokinetic (PK) analysis will be utilized to limit the number of blood draws with a sampling schedule of baseline (prior to the nerve block) through hospital discharge. There will be two collection sequences for this study and a subject can only be randomized to one sequence.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, at least 18 years of age at screening.
  2. Scheduled to undergo primary unilateral total shoulder arthroplasty or rotator cuff repair.
  3. Subjects scheduled for rotator cuff repair must have a magnetic resonance imaging (MRI) with a reading confirming a tear of at least 1 cm.
  4. (ASA) physical status 1, 2, or 3.
  5. Female subject must be surgically sterile; or at least 2 years ; or have a monogamous partner who is surgically sterile; or practicing double-barrier ; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening and commit to the use of an acceptable form of birth control for the duration of the study and for 30 days after completion of the study.
  6. Able to demonstrate normal motor function (by obtaining a 5 on the Lovett Scale when exhibiting biceps, wrist, and thumb movement) and sensory function (by exhibiting sensitivity to cold, pinprick, and light touch) in the location where sensory function will be measured throughout the study: 2 cm superior to the coracoid process on the skin overlying the acromioclavicular joint.
  7. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
  2. Planned concurrent surgical procedure.
  3. Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the shoulder surgery and which may confound the postsurgical assessments (e.g., significant pain from other joints, chronic neuropathic pain).
  4. History of or idiosyncratic reaction to amide-type local anesthetics.
  5. Smoking history of greater than 25 pack-years.
  6. to any one of the following: bupivacaine, oxycodone, morphine, or hydromorphone.
  7. Use of any of the following medications within the times specified before surgery: long-acting opioid medications or NSAIDs (except for low-dose aspirin used for cardioprotection) within 3 days, or any opioid medication within 24 hours.
  8. Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, he or she must be on a stable dose for at least 1 month prior to study drug administration.
  9. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
  10. Use of dexmedetomidine hydrochloride (HCl) (Precedex®) within 3 days of study drug administration.
  11. History of impaired kidney function, emphysema or other chronic respiratory disease, rheumatoid arthritis, coagulopathy, or loss of sensation in extremities.
  12. Impaired kidney function (e.g., serum creatinine level >2 mg/dL [176.8 µmol/L] or blood urea nitrogen level >50 mg/dL [17.9 mmol/L]) or impaired liver function (e.g., serum [AST] level >3 times the [ULN] or serum alanine aminotransferase [ALT] level >3 times the ULN.)
  13. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study assessments.
  14. Any chronic neuromuscular deficit effecting the peripheral nerves or muscles of the surgical extremity.
  15. Any chronic condition or disease that would compromise neurological or vascular assessments.
  16. in the last 2 years, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  17. Suspected or known history of drug or alcohol abuse within the previous year.
  18. Body weight \<50 kg (110 pounds) or a >44 kg/m2.
  19. Previous participation in an EXPAREL study.
  20. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Active comparator
    EXPAREL 133 mg

    10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively

    Drug: bupivacaine liposome injectable suspension

  • Active comparator
    EXPAREL 266 mg

    20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively

    Drug: bupivacaine liposome injectable suspension

  • Placebo comparator
    Placebo

    20 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores

    AUC of VAS pain intensity scores through 48 hours, which represents total pain experienced through 48 hours. VAS is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."

    Time frame: 0-48 hours

Secondary outcomes

  1. Total Postsurgical Opioid Consumption Through 48 Hours

    Total postsurgical opioid consumption (converted to IV morphine equivalents) through 48 hours

    Time frame: 0-48 hours

  2. Percentage of Opioid-free Participants Through 48 Hours

    Percentage of participants who did not receive opioid medication through 48 hours

    Time frame: 0-48 hours

  3. Time to First Opioid Rescue Through 48 Hours

    Time to first opioid rescue medication consumed through 48 hours. Time to rescue was estimated from Kaplan-Meier analysis and presented as quartiles (ie, time to rescue for the first 25% / 50% / 75% of subjects within each treatment group).

    Time frame: 0-48 hours

07

Results

Posted Dec 3, 2020

Participant flow

Participants were recruited between May 9, 2016 and July 7, 2017 at 16 sites in the US and Europe

Participant flow — Overall Study
MilestoneEXPAREL 133 mgEXPAREL 266 mgPlacebo
Started691571
Completed681571
Not completed100

Outcome measures

PrimaryArea Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores

AUC of VAS pain intensity scores through 48 hours, which represents total pain experienced through 48 hours. VAS is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."

Time frame:
0-48 hours
Reported as:
Least squares mean · cm*hr
Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores
cm*hrEXPAREL 133 mgPlacebo
Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores136.431 ± 12.090254.119 ± 11.768
Statistical analysis
  • EXPAREL 133 mg vs Placebo · ANOVA · p = <0.0001 · Lsmd: -117.688 · 95% CI -150.896 to -84.480
SecondaryTotal Postsurgical Opioid Consumption Through 48 Hours

Total postsurgical opioid consumption (converted to IV morphine equivalents) through 48 hours

Time frame:
0-48 hours
Reported as:
Least squares mean · mg
Total Postsurgical Opioid Consumption Through 48 Hours
mgEXPAREL 133 mgPlacebo
Total Postsurgical Opioid Consumption Through 48 Hours11.973 ± 2.26554.303 ± 10.053
Statistical analysis
  • EXPAREL 133 mg vs Placebo · ANOVA · p = <0.0001 · Lsm treatment ratio: 0.220 · 95% CI 0.131 to 0.371
SecondaryPercentage of Opioid-free Participants Through 48 Hours

Percentage of participants who did not receive opioid medication through 48 hours

Time frame:
0-48 hours
Reported as:
Count of participants · Participants
Percentage of Opioid-free Participants Through 48 Hours
ParticipantsEXPAREL 133 mgPlacebo
Percentage of Opioid-free Participants Through 48 Hours91
Statistical analysis
  • EXPAREL 133 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.008 · Treatment difference: 0.116 · 95% CI 0.032 to 0.200
SecondaryTime to First Opioid Rescue Through 48 Hours

Time to first opioid rescue medication consumed through 48 hours. Time to rescue was estimated from Kaplan-Meier analysis and presented as quartiles (ie, time to rescue for the first 25% / 50% / 75% of subjects within each treatment group).

Time frame:
0-48 hours
Reported as:
Number · hours
Time to First Opioid Rescue Through 48 Hours
hoursEXPAREL 133 mgPlacebo
First quartile0.70 (0.52 to 1.37)0.38 (0.30 to 0.47)
Median quartile4.15 (1.52 to 8.50)0.58 (0.48 to 0.68)
Third quartile18.82 (9.73 to 36.40)0.87 (0.72 to 1.00)
Statistical analysis
  • EXPAREL 133 mg vs Placebo · Log Rank · p = <0.0001

Adverse events

Collected over From screening to postsurgical day 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL 133 mg0/69 (0%)2/69 (2.9%)55/69 (79.7%)
EXPAREL 266 mg0/15 (0%)1/15 (6.7%)11/15 (73.3%)
Placebo0/71 (0%)1/71 (1.4%)55/71 (77.5%)
Most frequent serious events
Most frequent serious events
EventEXPAREL 133 mgEXPAREL 266 mgPlacebo
PancreatitisGastrointestinal disorders0/691/150/71
PneumoniaInfections and infestations1/690/150/71
GoutMetabolism and nutrition disorders1/690/150/71
Clostridium difficile colitisInfections and infestations0/690/151/71
Most frequent other events
Showing 10 of 20
Most frequent other events
EventEXPAREL 133 mgEXPAREL 266 mgPlacebo
NauseaGastrointestinal disorders17/693/1526/71
HypertensionVascular disorders2/693/156/71
PruritisSkin and subcutaneous tissue disorders3/691/1511/71
ConstipationGastrointestinal disorders6/692/159/71
Muscle twitchingMusculoskeletal and connective tissue disorders5/692/158/71
DizzinessNervous system disorders2/691/159/71
HeadacheNervous system disorders7/691/153/71
VomitingGastrointestinal disorders4/691/157/71
DysgeusiaNervous system disorders6/690/153/71
HypoesthesiaNervous system disorders6/690/151/71

Baseline characteristics

Safety population included all participants who received study drug, with analysis by actual treatment received.

Age, Continuous
Age, Continuous(years)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Mean60.6 ± 9.9461.4 ± 7.7358.5 ± 9.4859.7 ± 9.55
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Female2572355
Male44848100
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Hispanic or Latino3058
Not Hispanic or Latino641565144
Unknown or Not Reported2013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American1341532
White531154118
More than one race0000
Unknown or Not Reported2024
Region of Enrollment
Region of Enrollment(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Belgium73919
United States521053115
Denmark102921
Dominant hand
Dominant hand(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Left hand1011021
Right hand591461134
Visual Analog Scale Pain Score
Visual Analog Scale Pain Score(units on a scale)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Mean2.43 ± 2.6212.51 ± 2.6412.94 ± 2.5142.68 ± 2.570
American Society of Anesthesiologists classification
American Society of Anesthesiologists classification(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
11511430
23693782
31852043
Greater than or equal to 40000

2 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Horizon Research Group, Inc
    Mobile, Alabama 36608, United States
  • Denver Metro Orthopedics
    Englewood, Colorado 80113, United States
  • Jackson Memorial Hospital/University of Miami
    Miami, Florida 33136, United States
  • Pensacola Research Associates
    Pensacola, Florida 32504, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02215, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Fairview Hospital
    Cleveland, Ohio 44111, United States
  • Indiana Regional Medical Center
    Indiana, Pennsylvania 15701, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Chan Soon-Shiong Medical Center
    Windber, Pennsylvania 15963, United States
  • Hermann Drive Surgical Hospital
    Houston, Texas 77004, United States
  • Westside Surgical Hospital
    Houston, Texas 77027, United States
  • Plano Surgical Hospital
    Plano, Texas 75093, United States
  • Houston Physician's Hospital
    Webster, Texas 77598, United States
  • Southampton Orthopedics Sports Medicine
    Franklin, Virginia 23851, United States
  • Ziekenhuis Oost-Limburg
    Genk, 3600, Belgium
  • Aarhus University Hospital
    Aarhus, 8000, Denmark
  • Regionshospital Silkeborg
    Silkeborg, 8600, Denmark
09

References and documents

Publications

  • Patel MA, Gadsden JC, Nedeljkovic SS, Bao X, Zeballos JL, Yu V, Ayad SS, Bendtsen TF. Brachial Plexus Block with Liposomal Bupivacaine for Shoulder Surgery Improves Analgesia and Reduces Opioid Consumption: Results from a Multicenter, Randomized, Double-Blind, Controlled Trial. Pain Med. 2020 Feb 1;21(2):387-400. doi: 10.1093/pm/pnz103. PubMed 31150095 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2020, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2016
First posted
Mar 18, 2016
Start
May 9, 2016
Primary completionActual
Jul 7, 2017
CompletionActual
Jul 7, 2017
Results first posted
Dec 3, 2020
Last update
Dec 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02713230
Responsible party
Sponsor
First posted
Mar 18, 2016
Start date
May 9, 2016
Primary completion
Jul 7, 2017
Completion
Jul 7, 2017
Results posted
Dec 3, 2020
Last update
Dec 3, 2020

Study contacts

James B Jones, MD, PharmD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion